Research Interests
Pancreatic cancer is the 3rd most lethal cancer in the United States with a 5-year survival rate of only 11%. This lethality is likely due to pancreatic cancer’s late-stage diagnosis and resistance to traditional chemotherapies; therefore, it is imperative to discover novel treatments to improve therapeutic strategies. Recent research into genome-wide association studies for pancreatic cancer have revealed that up to 25% of patients have mutations in their DNA damage response pathways. My research interests involve leveraging the common DNA repair mutations found in pancreatic cancer in order to create synergistic combinations for slowing tumor growth, with the ultimate goal of improving patient outcomes.